Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
December 01 2022 - 4:40PM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:
CLLS), a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, will host a live webcast to review the Company’s
clinical data on the AMELI-01 study (evaluating UCART123) presented
at the ASH Annual Meeting, and provide a Company update, on
December 13, 2022.
The event will feature presentations by the
management team and will be followed by a Q&A.
Cellectis Live WebcastTuesday,
December 13, 20227:30am ET/1:30pm CETTo register and access the
live webcast:
https://lifescievents.com/event/cellectis-webcast/
Following the live webcast, a replay will be available under the
“Events and Webcasts” section on the Investor page of the Company’s
website:
https://cellectis.com/en/investors/events-and-webcasts/
About CellectisCellectis is a
clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to make therapeutic gene editing in
hemopoietic stem cells for various diseases. As a clinical-stage
biopharmaceutical company with over 22 years of experience and
expertise in gene editing, Cellectis is developing life-changing
product candidates utilizing TALEN®, its gene editing technology,
and PulseAgile, its pioneering electroporation system to harness
the power of the immune system in order to treat diseases with
unmet medical needs. Cellectis’ headquarters are in Paris, France,
with locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS). For more information, visit
www.cellectis.com. Follow Cellectis on social media: @cellectis,
LinkedIn and YouTube.
For further information, please
contact:
Media contacts: Pascalyne
Wilson, Director, Communications, +33 (0)7 76 99 14
33, media@cellectis.com Margaret Gandolfo, Senior Manager,
Communications, +1 (646) 628 0300
Investor Relation contact: Arthur
Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com Ashley R. Robinson, LifeSci
Advisors, +1 617 430 7577
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,”
“could,” “may” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements include statements about the ability to progress of our
clinical trials and to present any data from the trial; the
clinical outcomes which may materially change as more patient data
become available, and the potential benefits of our UCART product
candidates. These forward-looking statements are made in light of
information currently available to us and are subject to numerous
risks and uncertainties, including with respect to the numerous
risks associated with biopharmaceutical product candidate
development. With respect to our cash runway, our operating plans,
including product development plans, may change as a result of
various factors, including factors currently unknown to us.
Furthermore, many other important factors, including those
described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2021 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- Cellectis_Webcast_Announcement_ENGLISH
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From May 2024 to Jun 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jun 2023 to Jun 2024